Pfizer
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
16 May 2024
NEW HAVEN, Conn. and NEW YORK, May 16, 2024 – Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced updated clinical data from a Phase 1b combination cohort evaluating vepdegestrant
Pfizer Announces New Chief Strategy and Innovation Officer
07 May 2024
Pfizer Inc. (NYSE: PFE) today announced that Andrew Baum, M.D., will join the company as Chief Strategy and Innovation Officer, Executive Vice President. Dr. Baum will be a member of Pfizer’s Executiv
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
30 Apr 2024
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer Conversion to full approval from a
Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting
29 Apr 2024
More than 50 abstracts, including 11 oral presentations, span Pfizer’s robust portfolio of approved and pipeline therapies across its key tumor areas and core scientific modalities New five-year progr
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
26 Apr 2024
A one-time dose of BEQVEZ has reduced bleeds post-treatment compared to standard of care with a median of zero bleeds (range 0 to 19) after up to three years of follow-up, providing sustained bleed pr
Pfizer Announces 2024 Shareholder Meeting Preliminary Results
25 Apr 2024
NEW YORK, April 25, 2024 – Pfizer Inc. (NYSE: PFE) today held its Annual Meeting of Shareholders. Preliminary results from the Annual Meeting indicate that the company’s 12 director nominees were re-e
Pfizer Declares Second-Quarter 2024 Dividend
25 Apr 2024
Board of Directors approves quarterly cash dividend of $0.42 per share Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 second-quarter 2024 dividend on the company’
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
22 Apr 2024
EMBLAVEO® is the first β-lactam/β-lactamase inhibitor antibiotic combination approved in the European Union for treating serious infections in adult patients caused by multidrug-resistant Gram-negativ
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
15 Apr 2024
Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2024 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 25,
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
10 Apr 2024
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk. The vaccine was well-tolerated and demonstrated an immune response non
Featured
Company story – Quaker Oats
By Kiron Kasbekar | 08 Mar 2024
Quaker Oats is a company whose products I remember from my childhood days. Years before a foreign exchange crisis caused the Indian government to impose curbs on consumer product imports, we used to see a host of foreign brands in the Indian market. Including Quaker Oats, which I remember eating when I was a child, and which has been available for the past two decades or more.
How Quaker Oats grabbed customers’ attention
By Kiron Kasbekar | 07 Mar 2024
Quaker Oats, the American food products giant that was created in 1901 through the merger of many older oat millers, and was acquired by a bigger foods giant, Pepsi, in 2001, has been an innovative company. One example of its innovativeness shows in its packaging – the cereal box it launched in 1915.
Company story – Cunard Line
By Kiron Kasbekar | 12 Jan 2024
The Cunard Line started its life in Glasgow in 1839 as the British and North American Royal Mail Steam-Packet Company when Samuel Cunard was awarded the first British transatlantic steamship mail contract.
Samuel Slater – textile tycoon or traitor?
By Kiron Kasbekar | 26 Dec 2023
Samuel Slater is a name that holds significant importance in the annals of American industrial history. Often referred to as the ‘Father of the American Factory System’, Slater's contributions played a pivotal role in shaping the nation’s industrial landscape.
Underwood Typewriter Company – an icon of the past
By Kiron Kasbekar | 21 Dec 2023
You’ve probably never heard of Underwood typewriters. For the company folded up in 1963 – 60 years ago. You may not even have seen and handled a typewriter, unless someone in your family owned one.
The rise and fall of Chrysler
By Kiron Kasbekar | 16 Dec 2023
A century ago, the American automobile industry was more crowded than a vegetable market on a Sunday morning, with such a wide variety of stuff on sale that buyers were spoilt for choice. Buyers could pick and choose, bargain, pay up and drive out with the newly purchased vehicle.
TRW – the tide turned
By Kiron Kasbekar | 13 Dec 2023
There used to be an American company called Thompson Ramo Wooldridge Inc. This company, which was a global supplier of automotive systems, modules, and components to car and truck manufacturers, started small, as most companies do. Then, as the automotive industry grew bigger, so did TRW.
The rise and fall of Nokia
By Aniket Gupta | 07 Dec 2023
My interest is stories about dominant companies that failed all of a sudden. These companies were once etched into people’s minds but have since become a symbol of nostalgia. One such company, which was the biggest in its industry before it failed catastrophically, is Nokia.
Yahoo!: The first king of the internet
By Aniket Gupta | 01 Dec 2023
The year is 1994. You go to the internet to search for a particular website, but there is no Google that could be used to search your desired website. What do you do? The answer is that you use Yahoo.
.jpg)
